Limits...
The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.

Ko YH, Na KS, Kim CE, Kim SH, Jeon YW, Yi JS, Lee MS, Kim SG, Jeong HG, Jung HY - Psychiatry Investig (2014)

Bottom Line: Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed.BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea.

ABSTRACT

Objective: Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.

Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.

Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

No MeSH data available.


Related in: MedlinePlus

Mean change in the total cholesterol, TG, HDL, and LDL in both ITT sample and completers during switching to ziprasidone. *p<0.01. TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ITT: intent-to-treat sample.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225211&req=5

Figure 3: Mean change in the total cholesterol, TG, HDL, and LDL in both ITT sample and completers during switching to ziprasidone. *p<0.01. TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ITT: intent-to-treat sample.

Mentions: Regarding the lipid profile, serum TG levels were significantly reduced from baseline (143.9±101.7 mg/dL) to the endpoint (123.3±87.7 mg/dL; F=2.68, df=3, p=0.048); however, other lipid components did not significantly change over the study period (Figure 3). Among the completers, there was no significant change in the lipid profile over the study period.


The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.

Ko YH, Na KS, Kim CE, Kim SH, Jeon YW, Yi JS, Lee MS, Kim SG, Jeong HG, Jung HY - Psychiatry Investig (2014)

Mean change in the total cholesterol, TG, HDL, and LDL in both ITT sample and completers during switching to ziprasidone. *p<0.01. TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ITT: intent-to-treat sample.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225211&req=5

Figure 3: Mean change in the total cholesterol, TG, HDL, and LDL in both ITT sample and completers during switching to ziprasidone. *p<0.01. TG: triglyceride, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ITT: intent-to-treat sample.
Mentions: Regarding the lipid profile, serum TG levels were significantly reduced from baseline (143.9±101.7 mg/dL) to the endpoint (123.3±87.7 mg/dL; F=2.68, df=3, p=0.048); however, other lipid components did not significantly change over the study period (Figure 3). Among the completers, there was no significant change in the lipid profile over the study period.

Bottom Line: Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed.BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea.

ABSTRACT

Objective: Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.

Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.

Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

No MeSH data available.


Related in: MedlinePlus